• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

    5/7/25 8:26:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email

    The Company Intends to Request a Review of the Delisting Determination

    CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC ("NYSE American") stating that the NYSE Regulation has determined to commence proceedings to delist Palatin's common stock. The notice, issued under Section 1003(f)(v) of the NYSE American Company Guide, cites the low selling price of Palatin's common stock as the basis for delisting.

    Palatin Technologies, Inc.

    As a result, trading of Palatin's common stock on the NYSE American has been immediately suspended, and the shares will transition to the OTC Pink Market under the ticker symbol "PTNT" beginning on May 8, 2025.

    Palatin intends to appeal the delisting decision, although there can be no assurance that any such appeal will be successful. The Company has until May 14, 2025 to appeal the NYSE American's decision.

    "We are disappointed with the delisting determination," said Carl Spana, Ph.D., President and CEO of Palatin Technologies. "We continue to believe the Company has valuable assets and the actions of NYSE American will in no way deter our commitment to advance our business plan and increase stockholder value."

    Forward-looking Statements

    Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the transition of the Company's common stock to the OTC Pink Market and the Company's appeal of the NYSE American's delisting determination, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-notice-302449397.html

    SOURCE Palatin Technologies, Inc.

    Get the next $PTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Palatin Technologies Inc.

      10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/14/25 5:00:30 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Palatin Technologies Inc.

      424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:27:16 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:26:19 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      5/12/25 9:30:59 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP and CFO/COO Wills Stephen T sold $8,274 worth of shares (4,999 units at $1.66), decreasing direct ownership by 2% to 235,456 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      8/2/24 5:01:24 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 16,171 shares, decreasing direct ownership by 6% to 240,455 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      7/31/24 4:31:03 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      5/12/25 9:30:59 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      4/11/24 4:45:17 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care